ERBB2 and breast cancer: With respect to HER2+ BC, there have been significant therapeutic advances in the field over the last decade, with several potent targeted treatments clinically available, including trastuzumab and Lapatinib alone or in combination with chemotherapeutics and new agents targeting other related to HER2 pathways (6, 64).